WE SEE THE FUTURE FIRST

WE SEE THE FUTURE FIRST

Minerva Biotechnologies is focused on cancer and stem cell therapeutics. We are developing cancer immunotherapies targeting 80% of solid tumors and to prevent cancer metastasis

more info
patternframe

Welcome to Minerva Biotechnologies

Exploring the Space between Cancers and Stem Cells

Cancer Therapeutics

Cancer Therapeutics

Minerva's CAR T therapeutics will attack solid tumors that are MUC1* positive. This represents approximately 80% of all cancers.

learn more
Regenerative Medicine

Regenerative Medicine

Minerva’s stem cell discoveries will enable pharmaceutical companies to utilize regenerative medicine in a variety of diseases.

learn more
AlphaSTEM®

AlphaSTEM®

Using AlphaSTEM® iPSC generation is more efficient, cell expansion is faster, and differentiation efficiency is increased.

learn more

We See The Future First.

Minerva Biotechnologies Launches AlphaSTEM® , A Naïve Stem Cell Culture System

featured news

Minerva Biotechnologies Launches AlphaSTEM® , A Naïve Stem Cell Culture System

Minerva Biotechnologies, a leading cancer therapy and regenerative medicine company, today announced the launch of the AlphaSTEM® ...

Posted on February 14, 2017

view more DETAILS

Latest News

April 3, 2018

Minerva Biotechnologies Presenting at the American Association for Cancer Research (AACR)...

Dr. Cynthia Bamdad, CEO of Minerva Biotechnologies, will present a poster entitled,

March 5, 2018

Minerva Biotechnologies Announces CellSystems as European Distributor of AlphaSTEM™,...

February 26, 2018 09:00 AM Central European Time WALTHAM, Mass. USA -- Minerva

January 31, 2018

Now Hiring! (BS/MS) Cancer Cell Scientist

Cancer Cell Scientist (BS/MS) Minerva Biotechnologies is developing therapies

View All News

We See The Future First.

Sign Up For Our Mailing List.